Search | Clinical Trials Finder

Conditions: Candidiasis, Oral, HIV Infections
Interventions: Chlorhexidine gluconate; Drug
Lead sponsor: Procter and Gamble; Industry
Eligibility: 13 Years to 75 Years
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 5
States / cities: Los Angeles, California • San Francisco, California • Columbus, Ohio + 1 more

Conditions: Pneumonia, Pneumocystis Carinii, HIV Infections
Interventions: Trimetrexate glucuronate, Leucovorin calcium; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 12 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: Ends 2007
U.S. locations: 1
States / cities: Morris Plains, New Jersey

Conditions: Mycobacterium Avium-Intracellulare Infection, HIV Infections
Interventions: Nelfinavir mesylate; Drug
Lead sponsor: Agouron Pharmaceuticals; Industry
Eligibility: 13 Years and older
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 5
States / cities: San Diego, California • Torrance, California • Chicago, Illinois + 2 more

Conditions: Cancer
Interventions: entinostat; Drug
Lead sponsor: National Institutes of Health Clinical Center (CC); NIH
Eligibility: 18 Years and older
Enrollment: 75 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2008
U.S. locations: 3
States / cities: Bethesda, Maryland

Conditions: Candidiasis, Oral, HIV Infections
Interventions: Amphotericin B; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 13 Years and older
Enrollment: 70 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Ends 1998
U.S. locations: 30
States / cities: Birmingham, Alabama • Los Angeles, California • San Jose, California + 18 more

Conditions: HIV Infections
Interventions: Pentoxifylline; Drug
Lead sponsor: Community Research Initiative of New England; Other
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 1
States / cities: Brookline, Massachusetts

Conditions: HIV Infections
Interventions: Stavudine; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 2
States / cities: New York, New York

Conditions: HIV Infections
Interventions: Indinavir sulfate, Stavudine; Drug
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 540 participants
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 1
States / cities: Whitehouse Station, New Jersey

Conditions: HIV Infections, Chickenpox
Interventions: Sorivudine; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 2 Years to 17 Years
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 1
States / cities: Wallingford, Connecticut

Conditions: Brain and Central Nervous System Tumors, Carcinoma of Unknown Primary, Leukemia, Lymphoma, Unspecified Childhood Solid Tumor, Protocol Specific
Interventions: topotecan hydrochloride; Drug
Lead sponsor: Pediatric Brain Tumor Consortium; Network
Eligibility: 3 Years to 21 Years
Enrollment: 19 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2005
U.S. locations: 11
States / cities: San Francisco, California • Washington D.C., District of Columbia • Chicago, Illinois + 8 more

Conditions: Pneumonia, Pneumocystis Carinii, HIV Infections
Interventions: Atovaquone, Pentamidine isethionate; Drug
Lead sponsor: Glaxo Wellcome; Industry
Eligibility: 13 Years and older
Enrollment: 615 participants
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 5
States / cities: Maitland, Florida • Tampa, Florida • New York, New York + 2 more

Conditions: HIV Infections
Interventions: Indinavir sulfate, Saquinavir; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years and older
Enrollment: 144 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Ends 1998
U.S. locations: 16
States / cities: Palo Alto, California • San Francisco, California • Torrance, California + 10 more

Conditions: HIV Infections
Interventions: Lamivudine, Stavudine, Zidovudine, Didanosine; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 12 Years and older
Enrollment: 280 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Ends 1998
U.S. locations: 38
States / cities: Birmingham, Alabama • Los Angeles, California • Palo Alto, California + 27 more

Conditions: Acquired Immunodeficiency Syndrome, Alcoholism, HIV Infection, Neoplasm, Smoking
Interventions: Not listed
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: Not listed
Enrollment: 4,500 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 1996 – 2004
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: HIV Infections
Interventions: Aldesleukin; Drug
Lead sponsor: Chiron Corporation; Industry
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 1
States / cities: San Francisco, California

Conditions: HIV Infections
Interventions: Telinavir; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 21 Years and older
Enrollment: 48 participants
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 4
States / cities: San Diego, California • Miami, Florida • Baltimore, Maryland + 1 more

Conditions: HIV Infections
Interventions: Sulfamethoxazole-Trimethoprim, Zidovudine; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 50 Years
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Ends 1990
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: HIV Infections
Interventions: Delavirdine mesylate, Didanosine; Drug
Lead sponsor: Pharmacia and Upjohn; Industry
Eligibility: 14 Years and older
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 83
States / cities: Birmingham, Alabama • Berkeley, California • Fresno, California + 59 more

Conditions: HIV Infections
Interventions: Foscarnet sodium; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 13 Years and older
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Ends 1992
U.S. locations: 11
States / cities: Los Angeles, California • San Diego, California • Minneapolis, Minnesota + 6 more

Conditions: HIV Infections
Interventions: gp160 Vaccine (Immuno-AG), gp160 Vaccine (MicroGeneSys); Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years and older
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Ends 1996
U.S. locations: 4
States / cities: Palo Alto, California • San Jose, California • San Mateo, California + 1 more

Conditions: Candidiasis, Candidiasis, Esophageal, HIV Infections
Interventions: Fluconazole; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 13 Years and older · Female only
Enrollment: 400 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Ends 1995
U.S. locations: 16
States / cities: San Francisco, California • Denver, Colorado • Wilmington, Delaware + 11 more

Conditions: AIDS Dementia Complex, HIV Infections
Interventions: CPI-1189; Drug
Lead sponsor: Centaur Pharmaceuticals; Industry
Eligibility: 18 Years to 50 Years · Male only
Enrollment: 48 participants
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 1
States / cities: Phoenix, Arizona

Conditions: HIV Infections
Interventions: Abacavir sulfate; Drug
Lead sponsor: Glaxo Wellcome; Industry
Eligibility: 13 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 8
States / cities: Greenbrae, California • Los Angeles, California • San Francisco, California + 5 more

Conditions: HIV Infections
Interventions: Zidovudine, Zalcitabine; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years and older
Enrollment: 528 participants
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 24
States / cities: Harbor City, California • Los Angeles, California • San Diego, California + 19 more

Search by objective public record fields.

The Safety and Effectiveness of Peridex in Preventing or Delaying Fungal Infections of the Mouth in HIV-Infected Patients

A Treatment Protocol for the Use of Trimetrexate With Leucovorin Rescue for AIDS Patients With Pneumocystis Carinii Pneumonia and Serious Intolerance to Approved Therapies

A Study of Viracept in AIDS Patients With Mycobacterium Avium Complex Disease (MAC)

MS-275 in Treating Patients With Advanced Solid Tumors or Lymphoma

A Study of Amphotericin B in the Treatment of Fungal Infections of the Mouth in HIV-Infected Patients Who Have Not Had Success With Fluconazole

An Evaluation of Pentoxifylline in HIV-Positive Persons With Symptomatic HIV Infection and a Karnofsky Score > 40 Percent and < 100 Percent

A Study of BMY-27857 in Patients With AIDS or AIDS Related Complex

A Study of Indinavir Sulfate Given Together With Stavudine to HIV-Positive Patients

A Study of BV-araU in the Treatment of Varicella-Zoster Viral Disease (VZV) in HIV-Infected Children Who Have Not Had Success With or Who Cannot Take Other Treatments for VZV

Topotecan in Treating Young Patients With Neoplastic Meningitis Due to Leukemia, Lymphoma, or Solid Tumors

A Comparison of Atovaquone and Pentamidine in the Prevention of Pneumocystis Carinii Pneumonia in HIV-Infected Patients Who Cannot Take TMP/SMX

The Anti-HIV Effects of Saquinavir Soft Gelatin Capsules Versus Indinavir in Patients Who Have Used Saquinavir Hard Gelatin Capsules for One Year

Virologic Responses To New Nucleoside Regimens After Prolonged ZDV or ddI Monotherapy

Genetic Factors and Interrelationships for Cancer Risk-Related Behaviors and Complex Traits

A Phase I Study of Subcutaneously Administered Proleukin (Aldesleukin) in HIV-Infected Patients

A Phase I Randomized Dose/Formulation Comparison Study of SC-52151

Evaluation of the Interaction Between High Dose Sulfamethoxazole/Trimethoprim and Zidovudine

A Double-Blind, Randomized, Comparative Study of Delavirdine Mesylate (U-90152S) in Combination With Didanosine (ddI) Versus ddI Alone in HIV-1 Infected Individuals With CD4 Counts of <= 300/mm3

A Multicenter Study To Determine Foscarnet Dose Response in HIV Infected Patients With PGL and/or Constitutional Disease

A Phase I/II Study of Delayed-Type Hypersensitivity (DTH) Reactions to Intradermal HIV Envelope Antigen

A Randomized, Prospective, Double-Blind Study Comparing Fluconazole With Placebo for Primary and Secondary Prophylaxis of Mucosal Candidiasis in HIV-Infected Women

Safety and Effectiveness of CPI-1189 in HIV-Infected Males on Combination Anti-HIV Drug Therapy

A Study of 1592U89 Combined With Other Anti-HIV Drugs in Patients Who Have Taken Anti-HIV Drugs

A Randomized, Open-Label Study of Alternative Treatment Combinations of Dideoxycytidine (HIVID; ddC) and Zidovudine (AZT) in Patients With HIV Infection